A One-Year Partial Double-Blinded, Randomized, Multi-Center, Multi-National Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis.

Trial Profile

A One-Year Partial Double-Blinded, Randomized, Multi-Center, Multi-National Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Teriparatide; Zoledronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2011 Status changed from active, no longer recruiting to completed.
    • 01 Mar 2011 Results published in the Journal of Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top